Abivax: appointments to follow




By




Abivax remains stable at 13 euros, while the clinical-stage biotechnology company focused on the development of therapeutic treatments that exploit the body’s natural regulatory mechanisms in order to modulate the immune response in patients suffering from inflammatory diseases…

This stock market news is reserved for subscribers Privileges


Test our stock market advice for €1, without obligation


I subscribe

Already subscribed? Log in

Discover Boursier.com services Privileges


  • 8:30 a.m.
    Today’s recce

  • 4 to 5 stock market tips per day


    4 to 5 tips
    scholarship holders per day

  • weekly letter “Opportunities”


    Weekly letter “Opportunities”



  • Wallets
    defensive, balanced
    and dynamic


Learn more


©2023 Boursier.com



Source link -87